ALK-Abello A/S
CSE:ALK B

Watchlist Manager
ALK-Abello A/S Logo
ALK-Abello A/S
CSE:ALK B
Watchlist
Price: 225.2 DKK Market Closed
Market Cap: 45.6B DKK

EV/EBITDA
Enterprise Value to EBITDA

27.9
Current
26.8
Median
13.1
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
27.9
=
Enterprise Value
49.6B DKK
/
EBITDA
1.8B DKK
All Countries
Close
Market Cap EV/EBITDA
DK
ALK-Abello A/S
CSE:ALK B
49.9B DKK 27.9
US
Eli Lilly and Co
NYSE:LLY
954.7B USD 34.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 3 846.3
US
Johnson & Johnson
NYSE:JNJ
505.3B USD 16.4
CH
Roche Holding AG
SIX:ROG
252.4B CHF 11.5
UK
AstraZeneca PLC
LSE:AZN
210.9B GBP 108.4
CH
Novartis AG
SIX:NOVN
203.1B CHF 11.3
US
Merck & Co Inc
NYSE:MRK
245.9B USD 9.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 9.5
IE
Endo International PLC
LSE:0Y5F
202.5B USD 321.2
US
Pfizer Inc
NYSE:PFE
147.4B USD 7.6
EBITDA Growth EV/EBITDA to Growth
DK
ALK-Abello A/S
CSE:ALK B
Average EV/EBITDA: 400.4
27.9
22%
1.3
US
Eli Lilly and Co
NYSE:LLY
34.8
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.4
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.5
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.4
10%
10.8
CH
Novartis AG
SIX:NOVN
11.3
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.2
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.5
2%
4.8
IE
E
Endo International PLC
LSE:0Y5F
321.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
24.5
2-Years Forward
EV/EBITDA
22.3
3-Years Forward
EV/EBITDA
20